Thao Dang
Executive Director, Oncology Clinical Development Gilead Sciences
Seminars
Tuesday 13th October 2026
Trodelvy-Immunotherapy & Beyond: Delving Into Clinical Data & Vision to Utilize Combination Therapies to Empower New Heights of ADC Patient Impact
6:15 pm
- Contextualizing ADC combinations as the future of effective clinical approaches as more ADCs advance to standard of care oncology settings
- Exploring ongoing work into Trodelvy-immunotherapy clinical combinations, focused on urothelial bladder cancer
- Highlighting rationale and vision for novel combinations to unlock the prospect of to deliver new heights of ADC-powered patient impact
